Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in 2017, according ...

The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA). The approval was based on data ...

Patients with newly diagnosed giant cell arteritis (GCA) experience significant delays in accessing subcutaneous tocilizumab (TCZ), with an average wait of 43 days from medication request to ...

And if you do, then you've no doubt come across Meta AI. The tech giant has woven artificial intelligence into how you interact on these apps, including helping with posts and editing images.

The Janus kinase inhibitor was developed by scientists at AbbVie. Credit: © AbbVie Inc. All rights reserved. The US Food and Drug Administration (FDA) has granted ...

for the treatment of adults with giant cell arteritis (GCA). According to InvestingPro data, the company maintains strong financials with revenues of $57.4 billion and an impressive gross profit ...

Plus, news about the No­vo Nordisk Foun­da­tion and Tonix: Ab­b­Vie’s Rin­voq gets la­bel ex­pan­sion: The block­buster JAK in­hibitor won ap­proval in … ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.